Search research articles
Contact Us
Filters
Showing results (41-50 of 76) with videos related to
Page
of 8
Sort By:
The Journal of Molecular Diagnostics : JMD
|
November 26, 2015
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial
Chih-Jian Lih, David J Sims, Robin D Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology
|
December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 76) with videos related to
Sort By:
Page
of 8
The Journal of Molecular Diagnostics : JMD
|
November 26, 2015
Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial
Chih-Jian Lih, David J Sims, Robin D Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology
|
December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Page
of 8